| BRIDGEBIO PHARMA DL-,001 |
| USA |
| Gesundheit |
| US10806X1028 / A2PLX7 |
| 2CL (Frankfurt) / BBIO (NASDAQ) |
| FRA:2CL, ETR:2CL, 2CL:GR, NASDAQ:BBIO |
| - |
| https://bridgebio.com/ |
|
BridgeBio Pharma is a biopharmaceutical company that discovers, develops, and delivers transformative medicines for patients with genetic diseases and cancers with clear genetic drivers. The company operates through a distinctive decentralized hub-an..
>Volltext.. |
| 11999.9 Mio. EUR |
| 13809.69 Mio. EUR |
| 429.97 Mio. EUR |
| -425.3 Mio. EUR |
| -620.81 Mio. EUR |
| -3.24 EUR |
| 2336.82 Mio. EUR |
| 488.71 Mio. EUR |
| -381.87 Mio. EUR |
| 2.04 |
| 99.43% |
| -19.26% |
| - |
| - |
| - |
| BRIDGEBIO |
| 08.04.26 |